Search Results 171-180 of 17139 for Glucagon
... glucagon-like peptide (GLP) combo. Note: Other protocol defined Inclusion/Exclusion Criteria may apply. Eligibility last updated 12/05/2024. Questions ...
Use of any glucagon-like peptide-1 (GLP-1) receptor agonist within 30 days prior to screening. Myocardial infarction, stroke, hospitalisation for unstable ...
acarbose). Furthermore, by confining the recommendations to oral medications, another class of injectable medication – glucagon-like peptide-1 receptor agonists ...
Receipt of glucagon-like peptide-1 agonists. Adults lacking the capacity to consent for self. Lack of English fluency. Note: Other protocol defined ...
Has current glucagon product to treat severe hypoglycemia (injectable or nasal) at home (will provide prescription if they do not have one). Be willing to ...
Investigator plans to examine the gastrointestinal (GI) physiologic profile of Teduglutide, a Glucagon-like Peptide 2 Analog as a possible intestinotrophic ...
The first, glucagon-like peptide 1 (GLP-1), a gastrointestinal hormone, stimulates the pancreas to make more beta cells, which increases the amount of insulin ...
Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects. Am J ...
... glucagon-like peptide-1 (GLP-1) agonists and other medical treatments. For more information. Larson EL, et al. Simultaneous liver transplant and sleeve ...
Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes. Int J Cardiol. 2026 Feb 15; 445:134042 Epub ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!